Impact of OSA primary therapy on antihypertensive drugs use

Bruno Revol^{1

2

3}, Christel Castelli^{4

5}, Marie Joyeux-Faure^{1

2}, Jean-Louis Pépin^{1

2}

Affiliations

¹ HP2 Laboratory, Inserm U1300, Grenoble Alpes University, Grenoble, France.
² EFCR Laboratory, Pole Thorax and vessels, Grenoble Alpes University Hospital, Grenoble, France.
³ Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
⁴ UMR 5815, Laboratory of law and health economics, University of Montpellier, Montpellier, France.
⁵ Department of Languedoc Mutualité Nouvelles Technologies, Montpellier Beausoleil Clinic, Montpellier, France.

Comment

Bruno Revol et al. Sleep. 2022.

. 2022 Sep 8;45(9):zsac151.

doi: 10.1093/sleep/zsac151.

Bruno Revol^{1

2

3}, Christel Castelli^{4

5}, Marie Joyeux-Faure^{1

2}, Jean-Louis Pépin^{1

2}

¹ HP2 Laboratory, Inserm U1300, Grenoble Alpes University, Grenoble, France.
² EFCR Laboratory, Pole Thorax and vessels, Grenoble Alpes University Hospital, Grenoble, France.
³ Pharmacovigilance Department, Grenoble Alpes University Hospital, Grenoble, France.
⁴ UMR 5815, Laboratory of law and health economics, University of Montpellier, Montpellier, France.
⁵ Department of Languedoc Mutualité Nouvelles Technologies, Montpellier Beausoleil Clinic, Montpellier, France.

No abstract available

Comment on

Deprescribing antihypertensive drugs after starting OSA primary therapy?
Revol B, Castelli C, Ben Messaoud R, Coffy A, Bailly S, Jullian-Desayes I, Martinot JB, Martinot P, Joyeux-Faure M, Pépin JL. Revol B, et al. Sleep. 2022 May 12;45(5):zsac060. doi: 10.1093/sleep/zsac060. Epub 2022 Mar 25. Sleep. 2022. PMID: 35554591 No abstract available.
Deprescribing antihypertensive drugs after starting OSA primary therapy: "first do no net harm?".
Romigi A. Romigi A. Sleep. 2022 Sep 8;45(9):zsac138. doi: 10.1093/sleep/zsac138. Sleep. 2022. PMID: 35802048 No abstract available.